Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422497 | 1.00 | ACLY (0.36) | ACLYABCC4MAPTALDH1A1LMNA | |
| SCHEMBL17818301 | 0.82 | ACLY (0.37) | ACLYSLC6A2MMP12MMP13 | |
| SCHEMBL17818345 | 0.82 | ACLY (0.37) | ACLYSLC6A2MMP12MMP13 | |
| SCHEMBL28514799 | 0.81 | ACLY (0.34) | ACLYSLC6A2MMP12MMP13 | |
| SCHEMBL12984995 | 0.81 | ACLY (0.34) | ACLYSLC6A2MMP12MMP13 | |
| SCHEMBL17818330 | 0.81 | ACLY (0.34) | ACLYSLC6A2MMP12MMP13 | |
| SCHEMBL17818350 | 0.81 | ACLY (0.34) | ACLYSLC6A2MMP12MMP13 | |
| SCHEMBL17202123 | 0.80 | ALDH1A1 (0.36) | ACLYALDH1A1 | |
| SCHEMBL15764440 | 0.78 | CYP4F2 (0.36) | ALDH1A1LMNA | |
| SCHEMBL12985129 | 0.78 | CYP4F2 (0.36) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468957-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017216705-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2017-12-21 | — | — | WO | disclosed |
| US-20170355684-A1 | CRYSTALLINE ISOXAZOLE HYDROXAMIC ACID COMPOUNDS | NOVARTIS PHARMA AG (CH) | 2017-12-14 | — | — | US | disclosed |
| EP-3233843-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097995-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355684-A1 | CRYSTALLINE ISOXAZOLE HYDROXAMIC ACID COMPOUNDS | CUTA, MGAM, SQLE | ACLY 223/4885ABCC4 1522/4885MAPT 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.